The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The audit was completed with zero critical and zero major observations
The proposed transaction will be effected as a share swap
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
